Shares of Dianthus TherapeuticsDNTH surged to an 18-month high Monday after the company's autoimmune disease treatment succeeded in a midstage study. Now, Dianthus is planning to send its drug, ...

This past weekend I was in church and one of my pastor friends asked me an interesting question about mini roses. One of the characteristics of carnations is some of them look a lot like roses. He ...

Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase ...

Dianthus Therapeutics, Inc. (DNTH) shares soared 6.1% in the last trading session to close at $17.86. The move was backed by solid volume with far more shares changing hands than in a normal session.